Shukra Pharmaceuticals has informed that the Company is closing its Trading window for dealing in the securities of the Company by the Promoters, members of the Promoter Group, Directors, KMPs, Insiders, Designated and Connected persons and their immediate relatives from Wednesday, April 1, 2026 till 48 hours after the declaration of its Financial Results for the Quarter and Year ended March 31, 2026 pursuant to the provisions of the Clause 4(2) of Schedule B read with Regulation 9 of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to time) and SEBI Circular No. SEBV/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023 read with Company’s ‘Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by Designated Persons’ (Insider Trading Code). Accordingly, all the Designated persons (including dependants and immediate relatives as per code) and connected persons are advised not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window. The date of the Board Meeting in connection with publishing its Financial Results for the quarter and year ended March 31, 2026 will be announced in due course.

The above information is a part of company’s filings submitted to BSE.